2017
Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer.
Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Krop I, Tolaney S, Wagle N, Getz G, Meyerson M, Love J, Winer E, Lin N, Adalsteinsson V. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 1092-1092. DOI: 10.1200/jco.2017.35.15_suppl.1092.Peer-Reviewed Original ResearchTriple-negative breast cancerMetastatic triple-negative breast cancerCell-free DNAMetastatic TNBCFirst blood drawCopy number alterationsOverall survivalBlood drawBreast cancerPrimary triple-negative breast cancerTumor fractionMedian overall survivalBreast cancer subsetsIndependent prognostic markerPlasma samplesNovel therapeutic targetCopy number analysisNumber alterationsHazard ratioLiver metastasesGenome-wide copy number analysisMetastatic diagnosisBRCA statusPrognostic markerCancer subsets
2008
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clinical Cancer Research 2008, 14: 8010-8018. PMID: 19088017, DOI: 10.1158/1078-0432.ccr-08-1208.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancerRisk factorsTherapeutic approachesBasal-like breast cancerConventional cytotoxic therapyBasal-like subtypeNovel therapeutic targetClinical research programCytotoxic therapyClinical behaviorConventional agentsTherapeutic targetDistinct subtypesCancerImportant subgroupSubtypesPotential targetUnique subgroupClinical samplesMolecular biology platformsSubgroupsMolecular biologyDistinct outcomesFocus article